Early discontinuation of DTG/ABC/3TC and BIC/TAF/FTC single-tablet regimens: a real-life multicenter cohort study

References

• Siegel K, Lekas HM. AIDS as a chronic illness: psychosocial implications. AIDS. 2002;16(Suppl 4):S69–S76. PMID: 12699002.
   PubMed Web of Science ®Google Scholar
• Raffi F, Esser S, Nunnari G, Pérez-Valero I, Waters L. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens. HIV Med. 2016;17(Suppl 5):3–16.
   PubMed Web of Science ®Google Scholar
• Prieto P, Podzamczer D. Switching strategies in the recent era of antiretroviral therapy. Expert Rev Clin Pharmacol. 2019;12(3):235–247.
   PubMed Web of Science ®Google Scholar
• Fabbiani M, Zaccarelli M, Grima P, et al. Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients. BMC Infect Dis. 2014;14(1):26. PMID: 24418191; PMCID: PMC3897945.
   Google Scholar
• Fabbiani M, Zaccarelli M, Latini A, et al. Reduced risk of Efavirenz discontinuation in naïve patients starting first-line antiretroviral therapy with single tablet versus dual tablet regimen. HIV Med. 2016;17(5):385–389. PMID: 26394902.
   Web of Science ®Google Scholar
• European AIDS Clinical Society (EACS). Guidelines Version 10.1. Brussels: EACS; 2020. https://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html
   Google Scholar
• Fabbiani M, Borghetti A, Squillace N, et al. Integrase inhibitors use and CMV infection predict immune recovery in people living with HIV starting first-line therapy. J Acquir Immune Defic Syndr. 2021;86(1):119–127. PMID: 33027154.
   Web of Science ®Google Scholar
• Lombardi F, Belmonti S, Borghetti A, et al. Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients. HIV Res Clin Pract. 2019;20(3):92–98. PMID: 31478469.
   PubMedGoogle Scholar
• Trottier B, Lake JE, Logue K, et al. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, phase IIIb study [published correction appears in Antivir Ther. 2017;22(5):459–460]. Antivir Ther. 2017;22(5):295–305.
   Web of Science ®Google Scholar
• Sax PE, DeJesus E, Crofoot G, et al. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Lancet HIV. 2017;4(4):e154–e160. PMID: 28219610.
   PubMed Web of Science ®Google Scholar
• Daar ES, DeJesus E, Ruane P, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018;5(7):e347–e356. PMID: 29925490.
   PubMed Web of Science ®Google Scholar
• Molina J-M, Ward D, Brar I, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018;5(7):e357–e365.
   PubMed Web of Science ®Google Scholar
• Linee guida italiane sull’utilizzo della terapia antiretrovirale e la gestione diagnostico-clinica delle persone con infezione da HIV-1. https://www.salute.gov.it/imgs/C_17_pubblicazioni_2696_allegato.pdf
   Google Scholar
• Kityo C, Hagins D, Koenig E, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) in virologically suppressed HIV-1 infected women: a randomized, open-label, multicenter, active-controlled, phase 3, noninferiority trial. J Acquir Immune Defic Syndr. 2019;82(3):321–328.
   PubMed Web of Science ®Google Scholar
• Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063–2072.
   PubMed Web of Science ®Google Scholar
• Harris M. What did we learn from the bictegravir switch studies? Lancet HIV. 2018;5(7):e336–e337.
   Web of Science ®Google Scholar
• Ciccullo A, Baldin G, Borghi V, et al. Overall tolerability of integrase inhibitors in clinical practice: results from a multicenter Italian cohort. AIDS Res Hum Retrovir. 2021;37(1):4–10. PMID: 32998526.
   PubMed Web of Science ®Google Scholar
• Cid-Silva P, Llibre JM, Fernández-Bargiela N, Margusino-Framiñán L, et al. Clinical experience with the integrase inhibitors dolutegravir and elvitegravir in HIV-infected patients: efficacy, safety and tolerance. Basic Clin Pharmacol Toxicol. 2017;121(5):442–446.
   PubMed Web of Science ®Google Scholar
• Elzi L, Erb S, Furrer H, Cavassini M, et al. Adverse events of raltegravir and dolutegravir. AIDS. 2017;31(13):1853–1858.
   PubMed Web of Science ®Google Scholar
• Llibre JM, Montoliu A, Miró JM, et al. Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort. HIV Med. 2019;20(3):237–247. Mar
   PubMed Web of Science ®Google Scholar
• Max B. Update on HIV integrase inhibitors for the treatment of HIV-1 infection. Future Virol. 2019;14(10):693–709.
   Web of Science ®Google Scholar
• Brizzi MB, Chiampas TD, Michienzi SM, Young JD, Patel MC, Badowski ME. Real-world evaluation of the safety and tolerability of abacavir/dolutegravir/lamivudine in an incarcerated population. Int J STD AIDS. 2019;30(12):1163–1168.
   Web of Science ®Google Scholar